COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02715804




Registration number
NCT02715804
Ethics application status
Date submitted
17/03/2016
Date registered
22/03/2016
Date last updated
14/07/2020

Titles & IDs
Public title
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Secondary ID [1] 0 0
2015-004068-13
Secondary ID [2] 0 0
HALO-109-301
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pancreatic Ductal Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types
Cancer 0 0 0 0
Pancreatic

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Treatment: Drugs - Placebo
Treatment: Drugs - nab-Paclitaxel
Treatment: Drugs - Gemcitabine

Experimental: PAG: PEGPH20 + nab-Paclitaxel + Gemcitabine - Participants will receive 3.0 micrograms/kilogram (µg/kg) PEGPH20 as an intravenous (IV) infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 milligrams/square meter (mg/m^2) nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.

Placebo Comparator: AG: Placebo + nab-Paclitaxel + Gemcitabine - Participants will receive placebo matching to PEGPH20 as an IV infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 mg/m^2 nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.


Other interventions: Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
PEGPH20 will be administered as per the dose and schedule specified in the respective arms.

Treatment: Drugs: Placebo
Matching placebo for PEGPH20

Treatment: Drugs: nab-Paclitaxel
Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.

Treatment: Drugs: Gemcitabine
Gemcitabine will be administered as per the dose and schedule specified in the respective arms.

Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival - Overall survival was defined as the time from randomization until death from any cause. Overall survival was analyzed using Kaplan-Meier methods.
Timepoint [1] 0 0
From randomization until death from any cause (maximum exposure: 150.1 weeks for PAG, and 83.9 weeks for AG)
Secondary outcome [1] 0 0
Progression-Free Survival (PFS) - PFS was defined as the time from randomization until the first occurrence of radiological disease progression, as determined by the blinded Central Imaging Vendor (CIV) based on Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, or death from any cause during the treatment period. Disease progression was defined as at least a 20 percent (%) increase in sum of diameters of target lesions, taking as reference the smallest sum on study thus far, nadir (this included baseline sum if that was the smallest on study); Sum must also demonstrate an absolute increase of at least 5 millimeters (mm); Appearance of one or more new lesions; Unequivocal progression of existing non-target lesions. Surviving participants without disease progression were censored for PFS analysis at the date of last evaluable post-baseline tumor assessment. Surviving participants without any post-baseline disease assessment were censored on Day 1. PFS was estimated using Kaplan-Meier method.
Timepoint [1] 0 0
From the date of randomization until disease progression or death from any cause (maximum exposure: 150.1 weeks for PAG, and 83.9 weeks for AG)
Secondary outcome [2] 0 0
Objective Response Rate (ORR): Percentage of Participants With Objective Response - ORR was defined as percentage of participants who achieved either a complete response (CR) or partial response (PR) as determined by the blinded CIV based on RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions; Any pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Timepoint [2] 0 0
From the date of randomization until CR or PR (maximum exposure: 150.1 weeks for PAG, and 83.9 weeks for AG)
Secondary outcome [3] 0 0
Duration of Response (DOR) - DOR was defined as the time from the first objective response of CR or PR until disease progression (as determined by the blinded CIV based on RECIST version 1.1) or death within 14 days of last dose of study treatment or randomization. CR was defined as disappearance of all target and non-target lesions; Any pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study thus far, the sum must also demonstrate an absolute increase of at least 5 mm, or the appearance of one or more new lesions; and unequivocal progression of existing non-target lesions. DOR was analyzed using Kaplan-Meier methods.
Timepoint [3] 0 0
From date of first objective response (CR or PR) until date of first disease progression (maximum exposure: 150.1 weeks for PAG, and 83.9 weeks for AG)
Secondary outcome [4] 0 0
Number of Participants With Treatment-Emergent Adverse Events (AEs) - An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were defined as AEs that begin or worsen in severity during or after the participant's first dose of study treatment and no later than 30 days after the date of the last dose of study treatment and/or any treatment-related AE regardless of the onset date. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
Timepoint [4] 0 0
From administration of first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 150.1 weeks for PAG, and 83.9 weeks for AG)
Secondary outcome [5] 0 0
Number of Participants With Worst Post-Baseline Hematology and Chemistry (Clinical Laboratory Parameters) Severity Grade During the Study - Severity grade associated with a laboratory parameter value was determined using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening. Grade 0 indicates evaluable lab records but not fall into any CTCAE grade for certain CTCAE term. A worst post-baseline grade shift was defined as the worst change that occurred at any measured timepoint during study. Hematology abnormalities: anemia(hemoglobin decreased), lymphocyte count decreased, lymphocyte count increased, neutropenia(neutrophil count decreased), thrombocytopenia(platelet count decreased), and leukopenia(white blood cell decreased). Chemistry abnormalities: hypoalbuminemia, alkaline phosphatase increased, alanine aminotransferase increased, aspartate aminotransferase increased, hyperbilirubinemia, hypo- and hypercalcemia, creatinine increased, hypo- and hyperglycaemia, hypo- and hyperkalemia, hypo- and hypermagnesemia, hypo- and hypernatremia.
Timepoint [5] 0 0
From administration of first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 150.1 weeks for PAG, and 83.9 weeks for AG)
Secondary outcome [6] 0 0
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) - ECGs including clinical significance was evaluated by the Investigator. Criteria for clinical significance were as per investigator's discretion.
Timepoint [6] 0 0
From administration of first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 150.1 weeks for PAG, and 83.9 weeks for AG)
Secondary outcome [7] 0 0
Number of Participants With Clinically Significant Abnormalities in Vital Signs - Vital signs included measurement of blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), heart rate, and body weight. Criteria for clinical significance abnormalities were: Heart rate: <50 beats per minute (bpm), >120 bpm, >=30 bpm increase from baseline, >=30 bpm decrease from baseline. SBP: >140 millimeters of mercury (mmHg) and increase from baseline >20 mmHg, >180 mmHg, <90 mmHg and decrease from baseline >10 mmHg. DBP: >90 mmHg and increase from baseline >20 mmHg, >105 mmHg, <60 mmHg and decrease from baseline >10 mmHg. Change in weight: >=5% increase from baseline, >=5% decrease from baseline.
Timepoint [7] 0 0
From administration of first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 150.1 weeks for PAG, and 83.9 weeks for AG)

Eligibility
Key inclusion criteria
Inclusion criteria:

Participants must satisfy all the following inclusion criteria to be enrolled in the study:

1. Signed, written Institutional Review Board/Ethics Committee-approved Informed Consent
Form (ICF).

2. Stage IV PDA with histological or cytological confirmation of PDA.

3. Participants must be determined to be HA-high based on archived or fresh tumor core
biopsy or sample obtained after the participant has documented metastatic disease.
Biopsies/samples must meet the following requirements:

1. Pancreas tumor biopsies/samples obtained on or after the date that metastatic
disease is documented or tumor biopsies/samples from a metastatic lesion are
acceptable.

2. Tumor biopsies or samples must meet the requirements provided in the Study
Laboratory Manual with regard to tumor tissue architecture. Note: cytology
samples from fine needle aspirates without maintained tissue architecture or
brushing biopsies are not acceptable.

3. Tumor tissue (formalin-fixed paraffin-embedded [FFPE] block preferred) must
include enough tumor to make a minimum of 5-10 unstained, consecutive FFPE slides
(10 slides are preferred) of 1 archival block that meet specific tissue sample
requirements.

4. Radiographic confirmation of Stage IV PDA with at least 1 tumor metastasis measurable
on computed tomography (CT) scan or magnetic resonance imaging (MRI) per Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, excluding the
primary pancreatic lesion.

5. If a participant has had adjuvant/neoadjuvant therapy and/or therapy for locally
advanced disease (chemotherapy for non-metastatic pancreatic cancer in combination
with or without radiation therapy), tumor recurrence or disease progression must have
occurred no sooner than 6 months after completing the last dose of the aforementioned
therapies, provided all toxicities have returned to baseline or less than or equal to
(=) Grade 1.

6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

7. Life expectancy greater than or equal to (=) 3 months.

8. Age =18 years.

9. A negative urine or serum pregnancy test within 7 days before Cycle 1, Day 1 (C1D1;
first dose of study medication) if female participant is of childbearing potential.

10. Screening clinical laboratory values as follows:

1. Total bilirubin =1.5 times upper limit of normal (ULN) (participants with Gilbert
syndrome are eligible independent of bilirubin levels).

2. Aspartate aminotransferase (serum glutamic oxaloacetic transaminase) and alanine
aminotransferase (serum glutamic pyruvate transaminase) =2.5 times ULN, (if liver
metastases are present, then =5 times ULN is allowed).

3. Serum creatinine =2.0 milligrams/deciliter (mg/dL) or calculated creatinine
clearance =40 milliliters/minute (mL/min).

4. Serum albumin =2.5 grams/deciliter (g/dL).

5. Prothrombin time or international normalized ratio (INR) within normal limits
(±15%), unless participant takes warfarin, in which case prothrombin time or INR
result must be within therapeutic range.

6. Partial thromboplastin time (PTT) within normal limits (±15%).

7. Hemoglobin =9 g/dL (transfusion and erythropoietic agents allowed).

8. Absolute neutrophil count =1,500 cells/cubic millimeter (cells/mm^3).

9. Platelet count =100,000/mm^3.

11. For women of childbearing potential (WOCBP) and for men, agreement to use a highly
effective contraceptive method from the time of screening throughout the study until 1
month (WOCBP) or 6 months (men) after administration of the last dose of any study
medication. Highly effective contraceptive methods consist of prior sterilization,
intrauterine device (IUD), intrauterine hormone-releasing system (IUS), oral or
injectable contraceptives, barrier methods, and/or true sexual abstinence.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

Participants are ineligible for enrollment if they meet any of the following exclusion
criteria:

1. Clinical evidence of deep vein thrombosis (DVT), pulmonary embolism (PE) or other
known thromboembolic (TE) event present during the screening period.

1. Participants with superficial vein thrombosis are eligible.

2. Participants with visceral/splanchnic vein thrombosis are still eligible if, in
the opinion of the Investigator, the visceral/splanchnic vein thrombosis is
primarily associated with the anatomic location of the underlying disease of
metastatic pancreatic cancer (there must be primary or metastatic disease in
reasonable proximity to the thrombosis, and the Investigator determines that the
thrombosis is due to a local tumor event and not a coagulation issue).

2. Previous radiotherapy, surgery, chemotherapy, or investigational therapy for the
treatment of metastatic disease.

a. Palliative radiotherapy for pain control of metastatic bone lesions is allowed.

3. Known central nervous system involvement or brain metastases.

4. New York Heart Association Class III or IV cardiac disease or myocardial infarction
within the past 12 months.

5. History of cerebrovascular accident or transient ischemic attack.

6. Clinically significant pre-existing carotid artery disease.

7. Known infection with human immunodeficiency virus, or active infection with hepatitis
B or hepatitis C within the past 12 months.

8. Known allergy to hyaluronidase.

9. Current use of megestrol acetate or megestrol acetate-containing drugs (use within 10
days of Day 1).

10. Contraindication to heparin as per institutional guidelines.

11. Women currently pregnant or breastfeeding.

12. Intolerance to dexamethasone.

13. History of another primary cancer within the last 3 years with the exception of
non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical
carcinoma in-situ.

14. Any other disease, active, uncontrolled bacterial, viral or fungal infection requiring
systemic therapy, metabolic dysfunction, physical examination finding or clinical
laboratory finding that leads to reasonable suspicion of a disease or condition that
contraindicates the use of an investigational drug, or that may affect the
interpretation of the results, or that may render the participant at high risk for
treatment complications.

15. Immunization with a live vaccine up to 2 weeks prior to Day 1.

16. Hypersensitivity to the active substance or ingredients of PEGPH20, gemcitabine, and
nab-paclitaxel.

17. Inability to comply with study and follow-up procedures as judged by the Investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Bankstown-Lidcombe Hospital - Bankstown
Recruitment hospital [2] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment hospital [3] 0 0
St Vincent's Hospital - Darlinghurst
Recruitment hospital [4] 0 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [5] 0 0
Flinders Medical Centre - Bedford
Recruitment hospital [6] 0 0
Bendigo Health Care Group - Bendigo
Recruitment hospital [7] 0 0
Monash Health - Bentleigh East
Recruitment hospital [8] 0 0
Peninsula & South Eastern Haematology and Oncology Group - Frankston
Recruitment postcode(s) [1] 0 0
- Bankstown
Recruitment postcode(s) [2] 0 0
- Camperdown
Recruitment postcode(s) [3] 0 0
- Darlinghurst
Recruitment postcode(s) [4] 0 0
- St Leonards
Recruitment postcode(s) [5] 0 0
- Bedford
Recruitment postcode(s) [6] 0 0
- Bendigo
Recruitment postcode(s) [7] 0 0
- Bentleigh East
Recruitment postcode(s) [8] 0 0
- Frankston
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
District of Columbia
Country [8] 0 0
United States of America
State/province [8] 0 0
Florida
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Maryland
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Minnesota
Country [17] 0 0
United States of America
State/province [17] 0 0
Nevada
Country [18] 0 0
United States of America
State/province [18] 0 0
New Hampshire
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oklahoma
Country [24] 0 0
United States of America
State/province [24] 0 0
Pennsylvania
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Utah
Country [27] 0 0
United States of America
State/province [27] 0 0
Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
Washington
Country [29] 0 0
United States of America
State/province [29] 0 0
Wisconsin
Country [30] 0 0
Belgium
State/province [30] 0 0
Antwerpen
Country [31] 0 0
Belgium
State/province [31] 0 0
Brussels Capital Region
Country [32] 0 0
Belgium
State/province [32] 0 0
Oost-Vlaanderen
Country [33] 0 0
Belgium
State/province [33] 0 0
Vlaams Brabant
Country [34] 0 0
Belgium
State/province [34] 0 0
Liege
Country [35] 0 0
Brazil
State/province [35] 0 0
Minas Gerais
Country [36] 0 0
Brazil
State/province [36] 0 0
Rio Grande Do Sul
Country [37] 0 0
Brazil
State/province [37] 0 0
São Paulo
Country [38] 0 0
Brazil
State/province [38] 0 0
Barretos
Country [39] 0 0
Brazil
State/province [39] 0 0
Rio de Janeiro
Country [40] 0 0
Canada
State/province [40] 0 0
Ontario
Country [41] 0 0
Croatia
State/province [41] 0 0
Grad Zagreb
Country [42] 0 0
Croatia
State/province [42] 0 0
Zagreb
Country [43] 0 0
Czechia
State/province [43] 0 0
Brno-mesto
Country [44] 0 0
Czechia
State/province [44] 0 0
Královéhradecký Kraj
Country [45] 0 0
Czechia
State/province [45] 0 0
Olomoucký Kraj
Country [46] 0 0
Czechia
State/province [46] 0 0
Prague
Country [47] 0 0
Czechia
State/province [47] 0 0
Praha 5
Country [48] 0 0
Denmark
State/province [48] 0 0
South Denmark
Country [49] 0 0
Estonia
State/province [49] 0 0
Harjumaa
Country [50] 0 0
France
State/province [50] 0 0
Bretagne
Country [51] 0 0
France
State/province [51] 0 0
Franche-Comté
Country [52] 0 0
France
State/province [52] 0 0
Hérault
Country [53] 0 0
France
State/province [53] 0 0
Loire-Atlantique
Country [54] 0 0
France
State/province [54] 0 0
Puy-de-Dôme
Country [55] 0 0
France
State/province [55] 0 0
Rhône
Country [56] 0 0
France
State/province [56] 0 0
Val-de-Marne
Country [57] 0 0
France
State/province [57] 0 0
Angers Cedex 02
Country [58] 0 0
France
State/province [58] 0 0
Bordeaux
Country [59] 0 0
France
State/province [59] 0 0
Créteil
Country [60] 0 0
France
State/province [60] 0 0
Lyon Cedex
Country [61] 0 0
France
State/province [61] 0 0
Lyon
Country [62] 0 0
France
State/province [62] 0 0
Paris
Country [63] 0 0
France
State/province [63] 0 0
Île-de-France
Country [64] 0 0
Germany
State/province [64] 0 0
Baden-Württemberg
Country [65] 0 0
Germany
State/province [65] 0 0
Bayern
Country [66] 0 0
Germany
State/province [66] 0 0
Nordrhein-Westfalen
Country [67] 0 0
Germany
State/province [67] 0 0
Sachsen
Country [68] 0 0
Germany
State/province [68] 0 0
Berlin
Country [69] 0 0
Germany
State/province [69] 0 0
Essen
Country [70] 0 0
Germany
State/province [70] 0 0
Halle
Country [71] 0 0
Germany
State/province [71] 0 0
Hamburg
Country [72] 0 0
Germany
State/province [72] 0 0
Heidelberg
Country [73] 0 0
Hungary
State/province [73] 0 0
Baranya
Country [74] 0 0
Hungary
State/province [74] 0 0
Csongrád
Country [75] 0 0
Hungary
State/province [75] 0 0
Gyor-Moson-Sopron
Country [76] 0 0
Hungary
State/province [76] 0 0
Hajdú-Bihar
Country [77] 0 0
Hungary
State/province [77] 0 0
Budapest
Country [78] 0 0
Hungary
State/province [78] 0 0
Kaposvár
Country [79] 0 0
Israel
State/province [79] 0 0
HaMerkaz
Country [80] 0 0
Israel
State/province [80] 0 0
Tel-Aviv
Country [81] 0 0
Israel
State/province [81] 0 0
Yerushalayim
Country [82] 0 0
Israel
State/province [82] 0 0
Afula
Country [83] 0 0
Israel
State/province [83] 0 0
Beer Sheva
Country [84] 0 0
Israel
State/province [84] 0 0
Hadera
Country [85] 0 0
Israel
State/province [85] 0 0
Haifa
Country [86] 0 0
Israel
State/province [86] 0 0
Jerusalem
Country [87] 0 0
Israel
State/province [87] 0 0
Tel Hashomer
Country [88] 0 0
Italy
State/province [88] 0 0
Foggia
Country [89] 0 0
Italy
State/province [89] 0 0
Milano
Country [90] 0 0
Italy
State/province [90] 0 0
Cremona
Country [91] 0 0
Italy
State/province [91] 0 0
Genova
Country [92] 0 0
Italy
State/province [92] 0 0
Milan
Country [93] 0 0
Italy
State/province [93] 0 0
Padova
Country [94] 0 0
Italy
State/province [94] 0 0
Roma
Country [95] 0 0
Italy
State/province [95] 0 0
Verona
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Busan Gwang'yeogsi
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Daegu Gwang'yeogsi
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Gyeonggido
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Seoul Teugbyeolsi
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Incheon
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Seoul
Country [102] 0 0
Latvia
State/province [102] 0 0
Daugavpils
Country [103] 0 0
Latvia
State/province [103] 0 0
Riga
Country [104] 0 0
Lithuania
State/province [104] 0 0
Vilniaus Apskritis
Country [105] 0 0
Netherlands
State/province [105] 0 0
Limburg
Country [106] 0 0
Netherlands
State/province [106] 0 0
Amsterdam
Country [107] 0 0
Netherlands
State/province [107] 0 0
Hoofddorp
Country [108] 0 0
Netherlands
State/province [108] 0 0
Nijmegen
Country [109] 0 0
Poland
State/province [109] 0 0
Podkarpackie
Country [110] 0 0
Poland
State/province [110] 0 0
Lublin
Country [111] 0 0
Poland
State/province [111] 0 0
Warszawa
Country [112] 0 0
Spain
State/province [112] 0 0
Barcelona
Country [113] 0 0
Spain
State/province [113] 0 0
Madrid
Country [114] 0 0
Spain
State/province [114] 0 0
Navarra
Country [115] 0 0
Spain
State/province [115] 0 0
Valencia
Country [116] 0 0
Spain
State/province [116] 0 0
Zaragoza
Country [117] 0 0
Taiwan
State/province [117] 0 0
Taichung Municipality
Country [118] 0 0
Taiwan
State/province [118] 0 0
Changhua
Country [119] 0 0
Taiwan
State/province [119] 0 0
Tainan
Country [120] 0 0
Taiwan
State/province [120] 0 0
Taipei
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Cambridgeshire
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Glasgow City
Country [123] 0 0
United Kingdom
State/province [123] 0 0
London, City Of
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Midlothian
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Wirral
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Birmingham
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Cottingham
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Coventry
Country [129] 0 0
United Kingdom
State/province [129] 0 0
London
Country [130] 0 0
United Kingdom
State/province [130] 0 0
Rhyl
Country [131] 0 0
United Kingdom
State/province [131] 0 0
Withington

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Halozyme Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant
Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment),
compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in
participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal
adenocarcinoma (PDA).
Trial website
https://clinicaltrials.gov/show/NCT02715804
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
VP, Medical, Regulatory and Drug Safety
Address 0 0
Halozyme Therapeutics
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT02715804